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ABSTRACT
Background: Pyoderma gangrenosum (PG)
belongs to a group of neutrophilic dermatoses
and is often associated with systemic disorders.
The authors present a patient with a recalcitrant
PG that did not respond to systemic standard
therapies, and discuss further treatment options
with impact on quality of life.
Case Report: A 42-year-old woman with
recurrent PG since 2005 was presented to the
dermatology department in April 2010.
Systemic standard therapies including
azathioprine, corticosteroids, mycophenolate
mofetil, and cyclophosphamide in
combination with intensive topical treatment
showed to be ineffective. Hence, in October
2010 the authors discontinued any previous
systemic therapies and implemented a
subcutaneously-administered therapy with
adalimumab starting with 80 mg in week 0
and 40 mg in week 1, followed by 40 mg every
second week. Under this therapy the ulceration
got steadily smaller and healed nearly
completely within 64 weeks. However,
treatment with adalimumab is still ongoing,
with the intent of consolidation and treatment
success, but application intervals have been
extended to 4-week intervals. Therapy with
adalimumab was well tolerated without any
side effects and led to an increased quality of life
measured with the Dermatology Life Quality
Index.
Discussion: An immune-modulatory monotherapy
with adalimumab is a viable treatment option
for recalcitrant PG. Thanks to the easy
administration, rare side effects, and good
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INTRODUCTION
Pyoderma gangrenosum (PG) is an inflammatory
disease of uncertain etiology that belongs to a
group of neutrophilic dermatoses. PG usually
begins with pustules, red papules, plaques, or
nodules growing rapidly to ulcerations with
undermined purple-colored borders [1]. There is
no typical constellation in laboratory findings
nor are there specific features in histopathology.
The pathergy phenomenon is often positive
[1]. Extracutaneous manifestation involving
mucosal structures of the upper airways, the
eyes, or the genital area have been observed [2].
PG is often associated with systemic disorders
such as Crohn’s disease, colitis ulcerosa,
rheumatoid arthritis or rheumatoid arthritis-
like processes, and paraproteinemia. After
healing, PG lesions leave typical scars with a
knitted look.
The first therapeutic step is the use of local
and systemic corticosteroids. In extensive cases,




colchicine, or 5-aminosalicylate, can be used
with unpredictable and often poor outcomes [3].
CASE REPORT
A 42-year-old woman with recalcitrant PG was
first presented in the dermatology department
in April 2010. Her first PG lesion was in 2005 on
the lower leg, followed by an ulcer on the
hypogastric region also in 2005, and in 2008 on
the lower leg again. Systemic treatment with
steroids (starting with a daily dosage of 1 mg
methylprednisolone/kg between 2005 and
2008) and azathioprine (100 mg daily between
2005 and 2009) had been performed in the
past and resolved the lesions. A short-term
treatment with ciclosporine had to be
discontinued because of development of severe
hypertension. Azathioprine treatment was
stopped in 2009 after a period of 18 months,
as the patient did not develop any new lesions.
Evaluation for associated systemic diseases
including gastroduodenoscopy, coloscopy, and
rheumatological investigation was performed
repeatedly and showed to be inconspicuous.
Laboratory screening for anti-nuclear
antibodies, rheumatoid factors, and anti-cyclic
citrullinated peptide (CCP) antibodies was
negative.
The current PG lesion on the right lower leg
appeared in February 2010. At the first visit in our
department the ulceration measured 15 9 20 cm
and the borders were purple and undermined.
The patient suffered from excessive pain.
Azathioprine and corticosteroid treatment
during the previous 2 weeks had been
unsuccessful. The authors first increased the
corticosteroids (methylprednisolone in a daily
dosage of 1.5 mg/kg) in combination with
azathioprine (150 mg daily) and began a
systemic analgetic therapy with oxycodone.
The local therapy consisted of 0.1%
betamethasone ointment. At first, the lesions
responded, but by lowering the dosage of
methylprednisolone they got worse. Hence, the
dose of systemic steroids was increased again
(2 mg methylprednisolone/kg), azathioprine
was kept at a daily dosage of 150 mg per day,
and mycophenolate mofetil was initiated at a
daily dosage of 2,000 mg. After an initial
response the ulceration became bigger
(16 9 40 cm), deeper, and more painful again
and new small ulcerations appeared in the
hypogastric region. Then, a cyclophosphamide-
dexamethasone pulse therapy was initiated.
After the first pulse the ulcerations in the
hypogastric area resolved, but after the second
cycle of this therapy the patient noticed nausea,
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dizziness, and shortness of breath. Therefore, this
treatment was discontinued.
After excluding any contraindications
the authors implemented a subcutaneously-
administered therapy with adalimumab starting
with 80 mg in week 0 and 40 mg in week 1,
followed by 40 mg every second week in October
2010. The patient gave written informed consent
to the off-label use of adalimumab. The
ulceration measured 15 9 30 cm when starting
this treatment (Fig. 1a). Under this therapy, the
ulceration got steadily smaller and healed nearly
completely within 64 weeks (Fig. 1b). Systemic
therapy with oxycodone could be lowered after
41 weeks of treatment and finally stopped in
January 2012. However, treatment with
adalimumab was resumed, with the intent of
consolidation and treatment success, but
application intervals were extended to 4-week
intervals. Therapy with adalimumab was well-
tolerated without any side effects and led to an
increased quality of life, measured with the
Dermatology Life Quality Index (DLQI) (Fig. 2).
To the author’s knowledge this is the first case
report that shows an objective improvement in
quality of life by using the DLQI score.
DISCUSSION
New therapeutic strategies take into account
that patients with inflammatory bowel disease,
which is frequently associated with PG, present
increased levels of tumor necrosis factor-a
(TNF-a). Furthermore, PG itself seems to be
associated with high serum levels of TNF-a,
resulting from an abnormal T-cell response in
PG patients. Hence, several authors presumed
that inhibition of TNF-a could effectively treat
PG [4–7]. In recent years, a growing rate of case
reports about successful treatment of PG by the
use of TNF-a-inhibitors such as etanercept,
infliximab, and adalimumab have been published.
Fig. 1 Large pyoderma gangrenosum (PG) defect on the
right lower leg after failure of several standard therapies
and before treatment with adalimumab (a). PG almost
healed after 64 weeks of treatment with adalimumab (b)
Fig. 2 Dermatology Life Quality Index (DLQI) under
therapy with adalimumab. The red line shows the falling
tendency of DLQI values
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For most patients, adalimumab seems to be the
favored treatment option, because of the easy
administration (subcutaneously and every
second week only) and rare side effects.
Furthermore, Hubbard et al. [6] state that
the rate of antibody production against
adalimumab, a fully human product, is only
12% compared to 75% in the case of infliximab,
a chimeric monoclonal anti-TNF-a antibody. In
2007, Pomerantz et al. [7] published a case of a
61-year-old woman having a systemic reaction
to infliximab at the second dose and not
responding to etanercept. Under the treatment
with adalimumab, initially in combination with
prednisone 20 mg, the PG resolved within
5 months. Limitations of a therapy with
adalimumab are infectious diseases, especially
latent or active tuberculosis.
CONCLUSION
Due to several reports of successful treatment and
due to the author’s observations, adalimumab is a
viable treatment option for recalcitrant PG.
Owing to the easy administration, rare side
effects and good healing action it is a
convincing therapeutic strategy.
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